Prevalence and Molecular Characterization of Second-Line Drugs Resistance among Multidrug-Resistant Mycobacterium tuberculosis Isolates in Southwest of China

Table 2

Risk factors of second-line drug resistance among 156  isolates.

Characteristics	Number (%) of isolates ()	Number (%) of isolates		OR (95% CI)
		Sex
Female	35 (22.4)	21 (25.9)	14 (18.6)	—	—
Male	121 (77.6)	60 (74.1)	61 (81.3)	1.356 (0.635–2.894)	0.431
Age
29	29 (18.6)	17 (21.0)	12 (16.0)	—	—
30~39	33 (21.2)	19 (23.5)	14 (18.7)	1.044 (0.380–2.870)	0.934
40~49	40 (25.6)	19 (23.5)	21 (28.0)	1.566 (0.597–4.110)	0.361
50~59	25 (16.0)	16 (19.8)	9 (12.0)	0.797 (0.265–2.397)	0.686
60~69	21 (13.5)	5 (6.2)	16 (21.3)	4.533 (1.303–15.772)	0.014
≧70	8 (5.1)	5 (6.2)	3 (4.0)	0.850 (0.170–4.256)
District
Urban	79 (50.6)	36 (44.4)	43 (57.3)	—	—
Suburb	77 (49.4)	45 (55.6)	32 (42.7)	0.595 (0.316–1.122)	0.108
Treatment history
Previously treated failure	18 (11.5)	6 (7.4)	12 (16.0)	—	—
Previously treated	30 (19.2)	18 (22.2)	12 (16.0)	0.333 (0.098–1.132)	0.074
Retreatment failure	23 (14.7)	15 (18.5)	8 (10.7)	0.267 (0.072–0.9814)	0.043
Retreatment	85 (54.5)	42 (51.9)	43 (57.3)	0.512 (0.176–1.490)	0.214

is defined as Mycobacterium tuberculosis strain resistant to at least isoniazid and rifampin. isolate strain is resistant to one of the second-line drugs as follows: OFX, KAN, AMK, CAP, PTO, or PAS; isolate strain is susceptible to all of the second-line drugs as follows: OFX, KAN, AMK, CAP, PTO, and PAS. Previously treated failure cases, still sputum smear-positive after the whole treatment (6 months) or treatment for 5 months. Previously treated cases, still sputum smear-positive at the end of 3-month treatment. Retreatment failure case, still sputum smear-positive after the whole treatment (9 months) or treatment for 5 months. Retreatment cases, who were once cured but relapsed or were treated more than 1 month but treatment interruption was longer than 2 months; now accept treatment again; value from Fisher’s exact test.